These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 12644702)

  • 1. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Richman DD; Wrin T; Little SJ; Petropoulos CJ
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4144-9. PubMed ID: 12644702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P; Tranchat C; Tchou I; Pozzetto B; Lucht F; Desgranges C; Genin C
    J Infect Dis; 2000 May; 181(5):1607-13. PubMed ID: 10823760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
    Frost SD; Wrin T; Smith DM; Kosakovsky Pond SL; Liu Y; Paxinos E; Chappey C; Galovich J; Beauchaine J; Petropoulos CJ; Little SJ; Richman DD
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18514-9. PubMed ID: 16339909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of human immunodeficiency virus type 1 neutralization data.
    Nyambi PN; Nkengasong J; Lewi P; Andries K; Janssens W; Fransen K; Heyndrickx L; Piot P; van der Groen G
    J Virol; 1996 Sep; 70(9):6235-43. PubMed ID: 8709250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
    Sagar M; Wu X; Lee S; Overbaugh J
    J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    Sather DN; Armann J; Ching LK; Mavrantoni A; Sellhorn G; Caldwell Z; Yu X; Wood B; Self S; Kalams S; Stamatatos L
    J Virol; 2009 Jan; 83(2):757-69. PubMed ID: 18987148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
    Binley JM; Trkola A; Ketas T; Schiller D; Clas B; Little S; Richman D; Hurley A; Markowitz M; Moore JP
    J Infect Dis; 2000 Sep; 182(3):945-9. PubMed ID: 10950795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
    Zhang PF; Chen X; Fu DW; Margolick JB; Quinnan GV
    J Virol; 1999 Jun; 73(6):5225-30. PubMed ID: 10233993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.
    Cornelissen M; Euler Z; van den Kerkhof TL; van Gils MJ; Boeser-Nunnink BD; Kootstra NA; Zorgdrager F; Schuitemaker H; Prins JM; Sanders RW; van der Kuyl AC
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1135-1142. PubMed ID: 26910384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    Binley JM; Lybarger EA; Crooks ET; Seaman MS; Gray E; Davis KL; Decker JM; Wycuff D; Harris L; Hawkins N; Wood B; Nathe C; Richman D; Tomaras GD; Bibollet-Ruche F; Robinson JE; Morris L; Shaw GM; Montefiori DC; Mascola JR
    J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    Montefiori DC; Hill TS; Vo HT; Walker BD; Rosenberg ES
    J Virol; 2001 Nov; 75(21):10200-7. PubMed ID: 11581388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.